Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 541 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Arm B: Standard Treatment Clear all
Completed Early Phase 1 Interventional

Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

NCT03463408
View directory record Official record
Conditions
Sarcoma
Interventions
nivolumab, ipilimumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Completed Not applicable Interventional

Healing Touch or Guided Imagery In Treating Pain, Fatigue, Nausea, and Anxiety in Patients Undergoing Chemotherapy

NCT01553578
View directory record Official record
Conditions
Anxiety Disorder, Fatigue, Malignant Neoplasm, Nausea and Vomiting, Pain
Interventions
questionnaire administration, therapeutic touch, management of therapy complications, standard follow-up care
Other · Procedure · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 25, 2026, 2:34 PM EDT
Active, not recruiting Phase 2 Interventional

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04266249
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
Drug · Procedure · Biological + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
999
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MVA Post-Event: Administration Timing and Boost Study

NCT00437021
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 25, 2026, 2:34 PM EDT
Not yet recruiting Phase 3 Interventional

Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

NCT07629635
View directory record Official record
Conditions
Migraine Disease, Patent Foramen Ovale
Interventions
Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

NCT00206518
View directory record Official record
Conditions
Breast Cancer
Interventions
Taxotere/Docetaxel, Adriamycin/Cytoxan, doxorubicin
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 25, 2026, 2:34 PM EDT
Withdrawn Phase 2 Interventional

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure

NCT05633758
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Placebo, Metolazone
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 25, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

NCT02559778
View directory record Official record
Conditions
Neuroblastoma
Interventions
Ceritinib, dasatinib, sorafenib, vorinostat, DFMO
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
Up to 22 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2035
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Active, not recruiting Not applicable Interventional

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT02276443
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

NCT05472623
View directory record Official record
Conditions
Resectable Non-Small Cell Lung Cancer
Interventions
Adagrasib, Adagrasib/Nivolumab
Drug · Combination Product
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 25, 2026, 2:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Withdrawn Phase 2 Interventional

CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)

NCT06110598
View directory record Official record
Conditions
Pancreas Cancer, Pancreas Adenocarcinoma
Interventions
Capecitabine
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 25, 2026, 2:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Church-based HIV Screening: Taking It to the Pews

NCT02529644
View directory record Official record
Conditions
HIV
Interventions
Taking It to the Pews (Comparison), Taking It to the Pews (Experimental)
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years to 64 Years
Enrollment
1,540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 25, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

NCT02655601
View directory record Official record
Conditions
High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
Interventions
BMX-001, Radiation Therapy, Temozolomide
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 25, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Penclomedine in Treating Patients With Solid Tumors or Lymphoma

NCT00002946
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
penclomedine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 25, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

NCT01925612
View directory record Official record
Conditions
Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
Interventions
brentuximab vedotin, rituximab, vincristine, cyclophosphamide, prednisone, doxorubicin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 25, 2026, 2:34 PM EDT
Recruiting Not applicable Interventional

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

NCT06945042
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Arm A, Arm B
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

NCT00638612
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
AdV-tk, Valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Duarte, California • La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 25, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT07340541
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Completed No phase listed Observational

Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy

NCT06531876
View directory record Official record
Conditions
Narcolepsy Type 1, Hypersomnia, Sleep Disorder
Interventions
Dreem 3S recording
Device
Lead sponsor
Beacon Biosignals
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Fontana, California • Redwood City, California • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Completed Not applicable Interventional

A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis

NCT04595838
View directory record Official record
Conditions
Oral Mucositis
Interventions
Chemo Mouthpiece, Best Supportive Care only
Device · Other
Lead sponsor
Chemo Mouthpiece
Industry
Eligibility
18 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
11
States / cities
Costa Mesa, California • Goshen, Indiana • Farmington Hills, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 25, 2026, 2:34 PM EDT
Completed Not applicable Interventional Results available

Laryngeal Mask Airway in Laparoscopic Hernia Repair

NCT06023394
View directory record Official record
Conditions
Inguinal Hernia, Inguinal Hernia, Indirect, Inguinal Hernia Bilateral, Inguinal Hernia Unilateral
Interventions
Laryngeal Mask Airway, Endotracheal Tube Device
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Months to 8 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 25, 2026, 2:34 PM EDT
Active, not recruiting Not applicable Interventional

PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer

NCT03187951
View directory record Official record
Conditions
Other Disorders of Glucose Regulation and Pancreatic Internal Secretion, Pancreatic Cancer
Interventions
Questionnaires, Nutritional Questionnaire and Nutritional Counseling, Booklet, Aerobic Exercise and Strength Training Exercises, Phone Calls, Physical Assessments
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 25, 2026, 2:34 PM EDT
Recruiting Phase 1 Interventional

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT07225439
View directory record Official record
Conditions
Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
Interventions
Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide
Drug
Lead sponsor
Paolo Caimi, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 2:34 PM EDT